| Study name |
Efficacy of varenicline for smoking cessation among persistent smokers after coronary artery revascularization: a randomized placebo controlled clinical trial |
| Methods |
Double‐blind, randomised, placebo‐controlled trial |
| Participants |
600 participants that are male, > 18 years, and a current daily smoker of ≥ 5 CPD. Must also have a history of coronary artery revascularisation 9‐12 months prior to the study |
| Interventions |
Varenicline 0.5 mg once a day for 3 days, 0.5 mg twice a day for 4 days, 1 mg twice a day for 12 weeks Placebo, following same regimen |
| Outcomes |
Continuous smoking abstinence rate at the end of 26 weeks' follow‐up, by self‐report and validated by a close relative |
| Starting date |
22 August 2020 |
| Contact information |
Masoumeh Lotfi Tokaldany, +982188029256, lotfi213366@yahoo.co.uk |
| Notes |
Study funding: Tehran University of Medical Sciences |
